Use of pclx-001 or pclx-002 as a radiosensitizer
AssigneeAcylex Pharmaceuticals Inc.
InventorDeepak Karthesh DINAKARAN
Life of this patent
Estimating the term…
Abstract
Described herein is the use of PCLX-001, PCLX-002 or pharmaceutically acceptable salts thereof as a radiosensitizer of cancerous cells in a subject in need of radiation therapy. The radio sensitizer is applied to a subject with cancer undergoing radiotherapy, especially cancers of the brain, such as astrocytoma, glioma, embryonal tumour, non-malignant brain tumor, pediatric brain tumour, or metastatic tumours. The radiosensitizer is administered at dosing amounts to achieve blood, target organ or tumor drug concentrations in the range of about 50 nM to about 150 nM.
Claims67
Use of PCLX-001, or pharmaceutically acceptable salt thereof, for radiosensitizing a cancerous cell in a subject in need of radiation therapy.
Use of PCLX-001, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for radiosensitizing a cancerous cell in a subject in need of radiation therapy.
Use of a radiosensitizer, wherein the radiosensitizer is PCLX-001, and use of radiation therapy, for treating a subject with cancer, suspected of having a cancer, or at risk of developing a cancer.
Use of a radiosensitizer, wherein the radiosensitizer is PCLX-001, in the manufacture of a medicament, and use of radiation therapy, for treating a subject with cancer, suspected of having a cancer, or at risk of developing a cancer.
A method of radiosensitizing a cancerous cell in a subject in need of radiation therapy, comprising:
- administering to a subject compound PCLX-001, or pharmaceutically acceptable salt thereof.
A method of treating a subject with cancer, suspected of having a cancer, or at risk of developing a cancer, comprising administering a radiosensitizer, wherein the radiosensitizer is PCLX-001, and administering radiation therapy.
Dependencies are inferred from the claim text.